Targetting Signaling Pathways in Solid tumour Part B, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Contributors - p. iii 6. Chapter One: Cellular signaling in glioblastoma: A molecular and clinical perspective - p. 2 7. Chapter Two: Therapeutic potential of hedgehog signaling in advanced cancer types - p. 50 8. Chapter Three: An Overview of the Unfolded Protein Response (UPR) and Autophagy Pathways in Human Viral Oncogenesis - p. 82 9. Chapter Four: The crosstalk between miRNAs and signaling pathways in human cancers: Potential therapeutic implications - p. 134 10. Chapter Five: Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors - p. 169 11. Chapter Six: Mitochondria driven innate immune signaling and inflammation in cancer growth, immune evasion, and therapeutic resistance - p. 224
Targetting Signaling Pathways in Solid tumour Part B, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Contributors - p. iii 6. Chapter One: Cellular signaling in glioblastoma: A molecular and clinical perspective - p. 2 7. Chapter Two: Therapeutic potential of hedgehog signaling in advanced cancer types - p. 50 8. Chapter Three: An Overview of the Unfolded Protein Response (UPR) and Autophagy Pathways in Human Viral Oncogenesis - p. 82 9. Chapter Four: The crosstalk between miRNAs and signaling pathways in human cancers: Potential therapeutic implications - p. 134 10. Chapter Five: Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors - p. 169 11. Chapter Six: Mitochondria driven innate immune signaling and inflammation in cancer growth, immune evasion, and therapeutic resistance - p. 224
